InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,903.36
(
0.98%
)
Post# of 252428
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

WorstLuck

Send PM Follow Ignore
Followers 10
Posts 1031
Boards Moderated 0
Alias Born 02/23/2010

WorstLuck

Re: iwfal post# 252169

Friday, 06/14/2024 10:50:50 AM

Friday, June 14, 2024 10:50:50 AM

Post# of 252428
Just a comment on your point 2) regarding SOL-R without addressing the rest of the post.

1. The trial design is not finalized IIRC they still need a type C meeting.
2. This IS a re-dose trial, which is kind of a big deal and the primary reason for the trial IMO. You could consider non-inferiority as a co-primary reason. Note that the Axpaxli and comparator arms get redosed after 6 months.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up